Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 10
Submit an article Journal homepage
155
Views
16
CrossRef citations to date
0
Altmetric
Research Article

Drug Monitoring of PEG-Asparaginase Treatment in Childhood Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

J.P. Vieira Pinheiro Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Albert-Schweitzer-Strasse 33, 48129 Münster, Germany
,
C. Lanvers Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Albert-Schweitzer-Strasse 33, 48129 Münster, Germany
,
G. Würthwein Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Albert-Schweitzer-Strasse 33, 48129 Münster, Germany
,
R. Beier Department of Pediatric Hematology and Oncology, Medical School Hannover (ALL-BFM Study Center), 30625 Hannover, Germany
,
J. Casimiro da Palma Department of Pediatric Hematology and Oncology, Charité Campus Virchow Klinikum Berlin (ALL-BFM Relapse Study Center), 13353 Berlin, Germany
,
A. von Stackelberg Department of Pediatric Hematology and Oncology, Charité Campus Virchow Klinikum Berlin (ALL-BFM Relapse Study Center), 13353 Berlin, Germany
&
J. Boos Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Albert-Schweitzer-Strasse 33, 48129 Münster, Germany
 show all
Pages 1911-1920 | Published online: 03 Aug 2009

  • [Line 3514]Ettinger, L.J., Ettinger, A.G., Avramis, V.I. and Gaynon, P.S. (1997) "Acute lymphoblastic leukaemia: a guide to asparaginase and pegaspargase therapy", BioDrugs 7(1), 30-39.
  • [Line 3546]Haley, E.E., Fischer, G.A. and Welch, A.D. (1961) "The requirement for L-asparagine of mouse leukemia cells L5178Y in culture", Cancer Research 21, 532-536.
  • [Line 3576]Prager, M.D. and Bachynsky, N. (1968) "Asparagine synthetase in normal and malignant tissues: correlation with tumor sensitivity to asparaginase", Archives of Biochemistry and Biophysics 127(1), 645-654.
  • [Line 3606]Cooney, D. and Handschuhmacher, R. (1970) "L-asparaginase and L-asparagine metabolism", Annual Review of Pharmacology 10, 421-440
  • [Line 3635]Capizzi, R.L. (1993) "Asparaginase revisited", Leukemia and Lymphoma 10, 147-150.
  • [Line 3663]Müller, H.J. and Boos, J. (1998) "Use of L-asparaginase in childhood ALL", Critical Reviews in Oncology and Hematology 28(2), 97-113.
  • [Line 3693]Evans, W.E., Tsiatis, A., Rivera, G., Murphy, S.B., Dahl, G.V., Denison, M., Crom, W.R., Barker, L.F. and Mauer, A.M. (1982) "Anaphylactoid reactions to Escherichia coll and Erwinia asparaginase in children with leukemia and lymphoma", Cancer 49, 1378-1383.
  • [Line 3729]Oettgen, H.F., Stephenson, P.A., Schwartz, M.K., Leeper, R.D., Tallal, L., Tan, C.C., Clarkson, B.D., Golbey, R.B., Krakoff, I.H., Kamofsky, D.A., Murphy, M.L. and Burchenal, J.H. (1970) "Toxicity of E. coli L-asparaginase in man", Cancer 25, 253-278.
  • [Line 3768]Ohnuma, T., Holland, J.F. and Meyer, P. (1972) "Erwinia carotorova asparaginase in patients with prior anaphylaxis to asparaginase from E. coli", Cancer 30, 376-381.
  • [Line 3798]Billett, A.L., Carls, A., Gelber, R.D. and Sallan, S.E. (1992) "Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase", Cancer 70, 201-206.
  • [Line 3829]Kamisaki, Y., Wada, H., Yagura, T., Matsushima, A. and Inada, Y. (1981) "Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol", Journal of Pharmacology and Experimental Therapeutics 216, 410-414.
  • [Line 3861]Patel, S.S. and Benfield, P. (1996) "Pegaspargase (polyethylene, plycol-L-asparaginase)", Clinical Immunotherapeutics 5(6), 492-496.
  • [Line 3891]Asselin, B.L., Whitin, J.C., Coppola, D.J., Rupp, I.P., Sallan, S.E. and Cohen, H.J. (1993) "Comparative pharmacokinetic studies of three asparaginase preparations". Journal of Clinical Oncology 11, 1780-1786.
  • [Line 3924]Berg, S.L., Balis, F.M., McCully, C.L., Godwin, K.S. and Poplack, D.G. (1993) "Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey", Cancer Chemotherapy and Pharmacology 32, 310-314.
  • [Line 3956]Ho, D.H., Brown, S., Yen, A., Holmes, R., Kealing, M., Ahuchowski, A., Newman, R.A. and Krakoff, I.A. (1986) "Clinical pharmacology of polyethylene glycol-L-asparaginase", Drug Metabolism and Disposition 14, 349-352
  • [Line 3991]Boos, J., Werber, G., Ahlke, E., Schulze-Westhoff, P., Nowak-Göttl, U., Würthwein, G., Verspohl, E.J., Ritter, J. and Jürgens, H. (1996) "Monitoring of asparaginase activity and asparaginc levels in children on different asparaginase preparations". European Journal of Cancer 32A(9), 1544-1550.
  • [Line 4028]Schrappe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W.D., Henze, G., Gadner, H., Odenwald, E. and Riehm, H. (2000) "Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995", Leukemia 14, 2205-2222.
  • [Line 4064]Schrappe, M., Reiter, A., Ludwig, W.D., Harbott, J., Zimmermann, M., Hiddemann, W. Niemeyer, C., Henze, G., Feldges, A., Zintl, F., Komhuber, B., Ritter, J., Weite, K., Gadner, H. and Riehm, H. (2000) "Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of the trial ALL-BFM 90", Blood 95(11), 3310-3322.
  • [Line 4107]Riccardi, R., Holcenberg, J.S., Glaubinger, D.L., Wood, J.H. and Poplack, D.G. (1981) "L-Asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans". Cancer Research 41, 4554-4558.
  • [Line 4139]Boos, J. and Jürgens, H. (1996) "Pegaspargase (Polyethylene glyool-L-asparagiuase), a viewpoint", Clinical Immunotherapeutic 5, 497.
  • [Line 4166]Müller, H.J., Lönmg, L., Horn, A., Schwabe, D., Gunkel, M., Schrappe, M., von Schütz, V., Henze, G., Casimiro da Palma, J., Ritter, J., Vieira Pinheiro, J.P., Winkelhorst, M. and Boos, J. (2000) "Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols", British Journal of Haematology 110(2), 379-384.
  • [Line 4207]Vieira Pinheiro, J.P., Müller, H.J., Schwabe, D., Gunkel, M., Casimiro da Palma, J., Henze, G., von Schütz, V., Winkelhorst, M. and Boos, J. (2001) "Drug monitoring of low-dose PEG-asparapinase (Oncaspar?) in children with relapsed acute lymphoblastic leukaemia", British Journal of Haemololocy 113, 115-119.
  • [Line 4243]Müller, H.J., Beier, R., Casimiro da Palma, J., Lanvers, C., Ahlke, E., von Schülz, V., Gunkel, M., Horn, A., Schrappe, M., Henze, G., Kranz, K. and Boos, J. (2002) "PEG-asparaginase (Oncaspar) 2500 IU/m2 BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols", Cancer Chemotherapy and Pharmacology 49, 149-154.
  • [Line 4282]Lanvers, C., Vieira Pinheiro, J.P., Hempel, G., Wuerthwein, G. and Boos J. (2002). "Analytical validation of a microplate reader based method for the therapeutic drug monitoring of L-asparaginase in human serum", Analytical Biochemistry, accepted for publication.
  • Werber, G., Ahlke, E., Nowak-Göttl, U., Jürgens, H., Verspohl, E.J. and Boos, J. (1997) "Asparaginase activities in vitro are highly sensitive to different buffer conditions". In: Büchner, T., ed. Acute Leukemias VI: Prognostic Factors and Treatment Strategies (Springer, Berlin, Heidelberg), pp S512-S516.
  • [Line 4345]Holle, L.M. (1997) "Pegaspargase: an alternative?", Annals of Pharmacotherapy 31(5), 616-624.
  • [Line 4374]Keating, M.J., Holmes, R., Lerner, S. and Ho, D.H. (1993) "L-asparaginase and PEG asparaginase past, present and future", Leukemia and Lymphoma 10, 153-157.
  • [Line 4405]Ahlke, E., Nowak-Göttl, U., Schulze-Westhoff, P., Werber, G., Börste, H., Würthwein, G., Jürgens, H. and Boos, J. (1997) "Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia", British Journal of Haematology 96, 675-681.
  • [Line 4440]Vieira Pinheiro, J.P., Ahlke, E., Nuwak-Göttl, U., Hempel, G., Müller, H.J., Lümkemann, K., Schrappe, M., Rath, B., Fleischhack, G., Mann, G. and Boos, J. (1999) "Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols", British Journal of Haematology 104, 313-320.
  • [Line 4478]Asselin, B., Gelber, R. and Sallan, S. (1993) "Relative toxicity of E. coli L-asparaginase (ASP) and PRGasparaginase (PHG) in newly diagnosed childhood acute lymphoblastic leukemia (ALL)", Medical and Pediatric Oncology 21, 556.
  • [Line 4506]Ettinger, L.J., Asselin, B., Poplack, D.J. and Kurtzberg, J. (1993) "Toxicity profile of PEG-L-asparaginase in native-L-asparaginase hypersensitive and non-hypersensitive patients with acute lymphoblastic leukemia (ALL)", Medical and Pediatric Oncology 21, 556.
  • [Line 4535]Ettinger, L.J. and Lerner, E.D. (1994) "A toxicity study of Oncaspar'' (PEG-asparaginase) in children with acute lymphoblastic leukemia (ALL)", Medical and Pediatric Oncology 23(3), 278.
  • [Line 4563]Graham, M.L., Asselin, B.L., Herndon, 2nd, J.E., Casey, J.R., Chaffee, S., Ciocci, G.H., Daeschner, C.W., Davis, A.R., Gold, S., Halperin, E.C., Laughlin, M.J., Martin, P.L., Olson, J.F. and Kurtzberg, J. (1998) "Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia", Bone Marrow Transplantation 21(9), 879-885
  • [Line 4605]Greffe, B., Lambert-Kerzner, A. and Eno, M. (1993) "Hypercoagulable/prethrombotic state associated with PEG-L-asparaginase in pediatric leukemic patients", Thrombosis and Haemostasia 69, 335.
  • Pediatric Oncology GroupKurtzberg, J., Asselin, B., Pollack, B., Bernstein, M. and Buchanan, G. (1993) "PEG-L-asparaginase (PEGasp) vs native E. coli asparaginase (ASP) for reinduction of relapsed lymphoblastic leukemia (ALL): POG #8866 phase II trial", Proceedings of the American Society for Clinical Oncology 12, 323.
  • Kurtzberg, J., Asselin, B., Poplack, D., Grebamer, A., Chen, R., Franklin, A., Scudiery, D. and Fisherman, J. (1993) "Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy". Proceedings of the American Association for Cancer Research 34, 304.
  • [Line 4697]Kurtzberg, J. (1994) "A new look at PEG-L-asparaginase and other asparaginases in hematological malignancies", Cancer Investigation 12(Suppl. 1), 59-60.
  • [Line 4726]Vilmer, E., Suciu, S., Ferster, A., Bertrand, Y., Cave, H., Thyss, A., Benoit, Y., Dastugue, N., Fournier, M., Souillet, G., Manet, A.M., Robert, A., Nelken, B., Millot, E., Lutz, P., Rialland, X., Mechinaud, F., Boutard, P., Behar, C., Chantraine, J.M., Plouvier, E., Laureys, G., Brock, P., Uyttebroeck, A., Margueritte, G., Plantaz, D., Norton, L., Francolle, N., Gyselinck, J., Waterkeyu, C., Solbu, G., Philippe, N. and Otten, J. (2000) "Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report", Leukemia 14, 2257-2266.
  • [Line 4786]Abshire, T.C., Pollock, B.H., Billett, A.L., Bradley, P. and Buchanan, G.R. (2000) "Weekly polyethylene glycol conjugated L-asparapinase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study", Blood 96(5), 1709-1715.
  • [Line 4819]Ohnuma, L., Holland, J.F., Freeman, A. and Sinks, L.F. (1970) "Biochemical and pharmacological studies with asparaginase in man", Cancer Research 30, 2297-2305.
  • [Line 4850]Gerrits, G.P., Trijbels, F.J., Monnens, L.A., Gabreëls, F.J., de Abreu, R.A., Theeuwes, A.G. and van Raay-Selten, B. (1989) "Reference values for amino acids in cerebrospinal fluid of children determined using ion-exchange chromatography with fluorimetric detection", Clinica Chimica Acta 182, 271-280.
  • [Line 4884]Woo, M.H., Hak, L.J., Storm, M.C., Gajjar, A.J., Sandlund, J.T., Harrison, P.L., Wang, B., Pui, C.H and Relling, M.V. (1999) "Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia", Journal of Clinical Oncology 17(5), 1568-1573.
  • [Line 4921]Lepage, N., McDonald, N., Dallaire, L. and Lambert, M. (1997) "Age-specific distribution of plasma amino acid concentrations in a healthy pediatric population", Clinical Chemistry 43(12), 2397-2402.
  • [Line 4953]Schwartz, M.K., Lash, E.D., Oettgen, H.F. and Tomao, F.A. (1970) "L-Asparaginase activity in plasma and other biological fluids", Cancer 25, 244-252.
  • [Line 4984]Dibenedetto, S.P., Di Cataldo, A., Ragusa, R., Meli, C. and Lo Nigro, L. (1995) "Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia", Journal of Clinical Oncology 13, 339-344.
  • [Line 5016]Riuzari, C., Zucchetti, M., Conter, V., Diomede, L., Bruno, A., Gavazzi, L., Paganini, M., Sparano, P., Lo Nigro, L., Aricô, M., Milani, M. and D'Incalci, M. (2000) "L-Asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukaemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure", Annals of Oncology 11, 189-193.
  • [Line 5055]Gentili, D., Conter, V., Rizzari, C., Tschuemperlin, B., Zucchetti, M., Orlandoni, D., D'Incalci, M. and Masera, G. (1996) "L-Asparagine depletion in plasma and cerebrospinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia-Asparaginase", Annals of Oncology 7, 725-730.
  • Appel, I.M., den Boer, M.L., Reniers, N.C.M. and Pieters, R. (2002). "Determinants of asparaginase resistance in childhood acute lymphoblastic leukaemia, first results of pharmacokinetic data on asparaginase response". Abstract Book of the 3rd Biennial Hannover Symposium on Childhood Leukemia. Abstract No. 44.
  • [Line 5115]Killander, D., Dohlwitz, A., Engstedt, L., Franzen, S., Gahrton, G., Gullbring, B., Holm, G., Holmgren, A., Hßglund, S., Killander, A., Lockner, D., Mellstedt, H., Moe, P.J., Palmblad, J., Reizenstein, P., Skârberg, K.O., Swedberg, B., Udén, A.M., Wadman, B., Wide, M. and Åhström, L. (1976) "Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia", Cancer 37, 220-228.
  • [Line 5163]Woo, M.H., Hak, L.J., Storm, M.C., Sandlund, J.T., Ribeiro, R.C., Rivera, G.K., Rubnitz, J.E., Harrison, P.L., Wang, B., Evans, W.K., Pui, C.H. and Relling, M.V. (2000) "Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia", Journal of Clinical Oncology 18(7), 1525-1532.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.